4 profile pacjentów, w leczeniu których wybieram famotydynę Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2023
Słowa kluczowe:
famotydyna, choroby kwasozależne, NAB
##plugins.themes.bootstrap3.article.main##
Abstrakt
Przedstawione profile pacjentów wskazują na możliwość włączenia do leczenia famotydyny w celu optymalizacji terapii chorób kwasozależnych na podstawie dostępnych danych literaturowych i zaleceń praktycznych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Waśko-Czopnik , D. (2023). 4 profile pacjentów, w leczeniu których wybieram famotydynę . Medycyna Faktów , 16(1(58), 43-45. https://doi.org/10.24292/01.MF.0123.07
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. McCullough AJ, Graham DY, Knuff TE et al. Suppression of nocturnal acid secretion with famotidine accelerates gastric ulcer healing. Gastroenterology. 1989; 97(4): 860-6. http:// doi.org/10.1016/0016-5085(89)91489-3.
2. Ryan JR, Vargas R, McMahon FG et al. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med. 1986; 81(4B): 60-4. http://doi.org/10.1016/0002-9343(86)90601-7.
3. Yamashita Y, Kinoshita Y, Chihara K et al. [Comparison of the effects between standard doses of H2-blocker (famotidine 20 mg b.d.) and proton pump inhibitor (omeprazole 20 mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring]. Nihon Shokakibyo Gakkai Zasshi. 1994; 91(12): 2166-73.
4. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5(2): 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
5. Fandriks L, Lonroth H, Petterson A et al. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol. 2007; 42(6): 689-94. http://doi. org/10.1080/00365520601026665.
6. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987; 134: 55-60. http://doi.org/10.3109/00365528709090142.
7. Echizen H, Ishizaki I. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991; 21(3): 178-94. http://doi.org/10.2165/00003088-199121030-00003.
8. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991; 20(3): 218-36. http://doi.org/10.2165/00003088-19912003000004.
9. Mills JG, Wood JR. The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol. 1989; 11(suppl 1): 87-95.
2. Ryan JR, Vargas R, McMahon FG et al. Comparison of effects of oral and intravenous famotidine on inhibition of nocturnal gastric acid secretion. Am J Med. 1986; 81(4B): 60-4. http://doi.org/10.1016/0002-9343(86)90601-7.
3. Yamashita Y, Kinoshita Y, Chihara K et al. [Comparison of the effects between standard doses of H2-blocker (famotidine 20 mg b.d.) and proton pump inhibitor (omeprazole 20 mg o.d.) in the treatment of refractory reflux esophagitis by ambulatory 24-hr intra-gastroesophageal pH monitoring]. Nihon Shokakibyo Gakkai Zasshi. 1994; 91(12): 2166-73.
4. McRorie JW, Kirby JA, Miner PB. Histamine2-receptor antagonists: Rapid development of tachyphylaxis with repeat dosing. World J Gastrointest Pharmacol Ther. 2014; 5(2): 57-62. http://doi.org/10.4292/wjgpt.v5.i2.57.
5. Fandriks L, Lonroth H, Petterson A et al. Can famotidine and omeprazole be combined on a once-daily basis? Scand J Gastroenterol. 2007; 42(6): 689-94. http://doi. org/10.1080/00365520601026665.
6. Humphries TJ. Famotidine: a notable lack of drug interactions. Scand J Gastroenterol Suppl. 1987; 134: 55-60. http://doi.org/10.3109/00365528709090142.
7. Echizen H, Ishizaki I. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet. 1991; 21(3): 178-94. http://doi.org/10.2165/00003088-199121030-00003.
8. Lin JH. Pharmacokinetic and pharmacodynamic properties of histamine H2-receptor antagonists. Relationship between intrinsic potency and effective plasma concentrations. Clin Pharmacokinet. 1991; 20(3): 218-36. http://doi.org/10.2165/00003088-19912003000004.
9. Mills JG, Wood JR. The pharmacology of histamine H2-receptor antagonists. Methods Find Exp Clin Pharmacol. 1989; 11(suppl 1): 87-95.